Henry Schein, Inc. (NASDAQ:HSIC) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Monday.

According to Zacks, “Henry Schein exited third-quarter 2017 on a mixed note with earnings missing and revenues beating the Zacks Consensus Estimate. Apart from balanced growth across all its operating segments, Henry Schein's gains in the United States as well as overseas raise optimism. We are also positive about the company completing the buyout of Merritt Veterinary Supplies. On the flip side, the year-over-year deterioration in Henry Schein’s gross and operating margin due to higher cost of sales and expenses continues to be a concern. This apart, competitive pricing remains another cause of concern. We are disappointed with the company’s lowering of the high end of the 2017 EPS guidance indicating a gloomy scenario ahead. Over the last three months, the company has underperformed the broader industry.”

HSIC has been the subject of several other research reports. Credit Suisse Group reiterated a “hold” rating and issued a $87.50 price objective on shares of Henry Schein in a research note on Tuesday, August 29th. Jefferies Group LLC reiterated a “hold” rating and issued a $88.50 price objective on shares of Henry Schein in a research note on Thursday, September 28th. BidaskClub cut shares of Henry Schein from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Robert W. Baird set a $95.00 price objective on shares of Henry Schein and gave the stock a “buy” rating in a research note on Thursday, October 19th. Finally, Northcoast Research upgraded shares of Henry Schein from a “neutral” rating to a “buy” rating and set a $109.00 price objective for the company in a research note on Monday, August 7th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. Henry Schein has a consensus rating of “Hold” and a consensus target price of $89.88.

Henry Schein (NASDAQ:HSIC) traded down $2.61 during midday trading on Monday, hitting $67.05. 5,071,400 shares of the stock were exchanged, compared to its average volume of 1,106,182. The company has a current ratio of 1.55, a quick ratio of 0.86 and a debt-to-equity ratio of 0.30. The firm has a market cap of $10,523.79, a PE ratio of 18.81, a PEG ratio of 1.89 and a beta of 1.03. Henry Schein has a one year low of $67.02 and a one year high of $93.50.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Monday, November 6th. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). Henry Schein had a return on equity of 19.71% and a net margin of 4.52%. The company had revenue of $3.16 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same quarter in the prior year, the business posted $0.84 EPS. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. equities analysts anticipate that Henry Schein will post 3.6 EPS for the current fiscal year.

Henry Schein announced that its Board of Directors has initiated a stock repurchase plan on Monday, September 18th that authorizes the company to buyback $400.00 million in outstanding shares. This buyback authorization authorizes the company to repurchase up to 6.3% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s management believes its stock is undervalued.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/13/henry-schein-inc-hsic-cut-to-sell-at-zacks-investment-research.html.

In related news, SVP Paul Rose sold 2,126 shares of Henry Schein stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $172.51, for a total transaction of $366,756.26. Following the sale, the senior vice president now directly owns 17,841 shares in the company, valued at approximately $3,077,750.91. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 1.19% of the company’s stock.

Large investors have recently bought and sold shares of the stock. YorkBridge Wealth Partners LLC lifted its position in shares of Henry Schein by 5.2% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 570 shares of the company’s stock worth $104,000 after purchasing an additional 28 shares during the period. Sun Life Financial INC lifted its position in shares of Henry Schein by 8,185.7% in the 2nd quarter. Sun Life Financial INC now owns 580 shares of the company’s stock worth $106,000 after purchasing an additional 573 shares during the period. Lee Financial Co acquired a new position in shares of Henry Schein in the 2nd quarter worth approximately $161,000. Acrospire Investment Management LLC lifted its position in shares of Henry Schein by 150.0% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,000 shares of the company’s stock worth $183,000 after purchasing an additional 600 shares during the period. Finally, HM Payson & Co. acquired a new position in shares of Henry Schein in the 2nd quarter worth approximately $204,000. Institutional investors and hedge funds own 53.07% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Get a free copy of the Zacks research report on Henry Schein (HSIC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.